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Abstract  
 
Corticosteroids are the most effective treatment for asthma, but the therapeutic response 
varies markedly between individuals, with up to one third of patients showing evidence of 
insensitivity to corticosteroids. This article summarizes information on genetic, environmental 
and asthma-related factors as well as demographic and pharmacokinetic variables associated 
with corticosteroid insensitivity in asthma. Molecular mechanisms proposed to explain 
corticosteroid insensitivity are reviewed including alterations in glucocorticoid receptor 
subtype, binding and nuclear translocation, increased proinflammatory transcription factors 
and defective histone acetylation. Current therapies and future interventions that may 
restore corticosteroid sensitivity in asthma are discussed, including small molecule drugs and 
biological agents. In the future, biomarkers may be used in the clinic to predict corticosteroid 
sensitivity in patients with poorly controlled asthma. 
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1. Introduction 
 
Asthma is a chronic inflammatory disease of the airways that affects 300 million people 
worldwide. Both national and international guidelines recommend daily inhaled corticosteroid as 
the preferred controller treatment for adults and adolescents with asthma who have poor 
symptom control or who at risk of exacerbations [201, 202]. Inhaled corticosteroid use in asthma 
reduces symptoms, improves quality of life and increases lung function as well as decreases the 
rate of exacerbations [201, 202]. The majority of the therapeutic benefits of inhaled 
corticosteroids are achieved at low to medium doses [1], although higher doses are often 
required in patients with more severe asthma [2] [202].  Short courses of oral corticosteroids are 
administered to treat severe exacerbations and daily oral corticosteroids are used in the lowest 
dose providing adequate control to treat patients with severe asthma when symptoms are 
uncontrolled despite maximal therapy [201, 202]. 
 
Guideline recommendations for inhaled and oral corticosteroid use in asthma are based on 
average therapeutic responses from clinical trial populations that may not be representative of 
‘real-life’ patients [3]. Numerous studies in adults and children with asthma have noted a 
considerable patient-to-patient variability in improvements in lung function and airway 
hyperreactivity with inhaled and oral corticosteroid treatment in patients with apparently similar 
levels of disease severity [4-6] (Figure 1). The findings from these studies suggest that 
corticosteroid insensitivity may be present in approximately one third of patients with asthma. 
Inhaled corticosteroids exhibit a linear dose-response for systemic adverse effects [7] and high 
doses are associated with adrenal suppression [1,8], reduced bone mineral density and increased 
risk of fractures  as well as diabetes and reactivation of tuberculosis [9]. To improve the 
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therapeutic ratio for corticosteroid use in asthmatic patients who have an impaired clinical 
responses to corticosteroids there is a need to understand the causes of corticosteroid 
insensitivity and how best to manage these patients. This article reviews published information 
on factors associated with corticosteroid insensitivity in asthma, considers the molecular 
mechanisms proposed to explain corticosteroid insensitivity and discusses current therapies and 
future interventions that may restore corticosteroid sensitivity in asthma. 
 
2. Factors associated with corticosteroid insensitivity in asthma  
 
Corticosteroid insensitivity is an imprecise term used to describe an impaired response to 
corticosteroids, whereas corticosteroid resistance implies the absence of any response to 
corticosteroids.  A range of in vivo and in vitro biomarkers have been used to assess the 
response to corticosteroids in man, although none are ideal. The variation in corticosteroid 
sensitivity in people with asthma is most commonly measured using clinical outcomes such as 
symptoms, lung function and exacerbations [6]. A composite phenotype that includes 
information on inhaled corticosteroid treatment response in patients with mild to moderate 
asthma assessed by six outcomes (lung function, bronchodilator response, airway 
responsiveness, symptoms, need for oral corticosteroids and frequency of emergency 
department visits and hospitalizations) is reported to identify endophenotypes that more 
accurately describe corticosteroid sensitivity [10]. Sputum eosinophils, transcription factor 
gene expression levels on airway cells [11] and exhaled nitric oxide [12] as well as bronchial 
allergen challenge [13], exhaled breath profiling [14], urinary biomarkers [12] and the 
cutaneous vasoconstrictor response to topical corticosteroid [15] have been employed to 
measure variability in corticosteroid sensitivity in asthma. In vitro tests of corticosteroid 
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induced suppression of peripheral blood mononuclear cell (PBMC) T lymphocyte 
proliferation [16] and expression of transcription factors on cells [16,17] or composites in 
vitro measurements [18] have be used as biomarkers of corticosteroid sensitivity, although 
the ability of these tests to predict clinical responses to corticosteroids in the general 
population of patients with asthma is uncertain. 
 
Genetic, environmental and asthma associate factors as well as demographic and 
pharmacokinetic variables may contribute to differences in sensitivity to corticosteroids 
between people with asthma (Table 1). Variations in corticosteroid sensitivity are also found 
in healthy people.  
 
Genetic factors 
 
Genetic variants of the glucocorticoid receptor (GR) gene are implicated in differences in 
corticosteroid sensitivity in healthy subjects and some inflammatory diseases, although GR 
polymorphisms have not been reported in corticosteroid resistant asthma. Single-nucleotide 
polymorphisms (SNPs) of genes affecting the corticosteroid pathway have been described in 
children with asthma recruited to the Childhood Asthma Management Program (CAMP) and 
in replication populations. The CAMP study followed children with asthma who were treated 
with inhaled corticosteroids over a 4-year period with efficacy outcomes including 
improvements in FEV1, airway responsiveness to methacholine and the protection from 
exacerbations [19]. SNP variants associated with altered therapeutic response to treatment 
with inhaled corticosteroids include T-box expressed in T cells21 (TBX21) [20], corticotrophin-
releasing hormone receptor 1 gene (CRHR1) [21], low-affinity IgE receptor gene (FCER2) [22] 
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and glucocorticoid-induced transcript 1 gene (GLCCI1) [23]. Genome-wide association 
studies (GWAS) have identified novel pharmacogenetic loci associated with variations in 
response to inhaled corticosteroids including T gene SNPs [24] and SNPs chr6 rs6924808 and 
chr11 rs1353649 [25]. Genes implicated in fetal lung development are also associated with 
corticosteroid treatment response [26]. The contribution of a single SNP to explaining 
corticosteroid insensitivity in the total asthma population is likely to be small, whereas 
combinations of polymorphisms in corticosteroid sensitive genes may have a more important 
effect on the therapeutic response to corticosteroids. 
 
Environmental factors 
 
Cigarette smoke 
Corticosteroid insensitivity is an important clinical feature of current smokers with asthma 
[27-31]. Asthmatic smokers are less responsive to short and medium term treatment with 
inhaled or oral corticosteroids when assessed by improvements in symptoms, lung function 
and exacerbation rates compared to asthma patients who do not smoke [27-32]. Long-term 
treatment with inhaled corticosteroids however, may have beneficial effects in smokers with 
asthma by reducing the rate of decline in lung function [32-35]. Although insensitivity to 
inhaled corticosteroids is likely to contribute to poor asthma control in smokers, there are a 
number of unresolved issues regarding this phenomenon including the observation that not 
all smokers with asthma show insensitivity to short-term corticosteroid therapy, possibly due 
to differences in airway inflammation or intensity of smoking.  The relationship between the 
intensity of exposure to cigarette smoke, either daily or cumulatively, and the development 
of corticosteroid insensitivity is not clearly established. Most studies that report a reduced 
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responsiveness to corticosteroids have recruited patients with a heavy smoking history of 
greater than 10 pack years.  
 
A history of exposure to secondhand smoke in utero is associated with a reduced 
improvement in airway responsiveness to inhaled corticosteroids in children recruited to the 
CAMP study [36]. The mechanism underlying the attenuated response to inhaled 
corticosteroids in not known, although exposure to secondhand smoke in utero may 
adversely affect both the structure and function of the airways. 
 
Allergen exposure  
GR binding affinity of PBMCs from ragweed sensitive asthmatic subjects is reduced during the 
ragweed season when compared to before and after the pollen season [37]. In contrast, 
natural exposure to birch pollen does not reduce the ability of glucocorticoids to inhibit 
granulocyte-macrophage colony-stimulating factor production from PBMCs from subjects 
with seasonal allergic asthma and rhinitis due to birch pollen [38]. Severe asthma in children 
with fungal sensitization is associated with elevated airway interleukin (IL)-33 concentrations, 
which has been shown to induce corticosteroid insensitivity in a mouse model of asthma after 
exposure to the fungus Alternaria alternata [39]. Based on the current evidence, the 
importance of allergen exposure in corticosteroid insensitivity in vivo in asthma remains to be 
clearly established. 
 
Infections 
Toxins expression by microbes, called superantigens, are proposed as a possible mechanism 
by which infection could induce corticosteroid insensitivity [40]. Superantigens inhibit 
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corticosteroid-induced translocation of GRα to the cell nucleus [40] and increase the 
numbers of nonfunctioning GRβ [41]. Alteration to the airway microbiome has been 
implicated in corticosteroid responsiveness in asthma [42]. Corticosteroid-resistant asthma is 
associated with classical antimicrobial activation of airway macrophages [43] and expansion 
of specific gram-negative bacteria, which in vitro induce activate of mitogen-activated protein 
kinase (MAP) and corticosteroid insensitivity [42]. In a mouse model, the microbial agonists 
lipopolysaccharide (LPS) and β-glucan act synergistically with house dust mite to induce a 
corticosteroid insensitive neutrophilic inflammation though toll-like (TL)-4 and dectin-1 
receptors [44].   
 
Virus-induced exacerbations including rhinovirus infection are insensitive to treatment with 
corticosteroids, especially in children with asthma [45]. Rhinovirus infection causes 
corticosteroid insensitivity in airway epithelium through induction of nuclear factor κB (NFκB) 
and c-Jun N-terminal kinase (JNK) activation [46] and in monocyte cell lines through a 
reduction in histone deacetylase (HDAC)2 activity [47]. The clinical importance of 
superantigens, the airway microbiome and viruses in inducing corticosteroid resistance in 
asthma remains to be established. 
 
Endotoxin 
Increased sputum endotoxin concentrations are associated with an impaired lung function 
response to oral corticosteroids, particularly in never smokers with asthma, which suggests 
that airway endotoxin may contribute to corticosteroid insensitivity in asthma [48] (Figure 2). 
Patients with asthma may be exposed to endotoxin in household dust, through certain 
occupations such as cotton textile workers or farm animal workers and in cigarette smoke, 
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either as active smokers or by exposure to secondhand smoke. Increased bacterial load 
within the airways or increased airway permeability might also increase airway endotoxin 
concentrations in asthma.  
 
Vitamin D deficiency 
Reduced vitamin D concentration in asthma are associated with reduced lung function, 
increased airway hyperresponsiveness and impaired corticosteroid sensitivity, when 
measured by dexamethasone-induced expression of mitogen-activated protein kinase 
phosphatase (MKP)1 by PBMCs [49].  
 
Asthma associated factors 
 
Airway inflammatory cell phenotypes and airway remodeling 
Eosinophilic airway inflammation, identified by the presence of sputum or blood eosinophilia, 
predicts patients with asthma who are likely to obtain a favorable therapeutic response to 
corticosteroids.  The type 2 helper T-cell (Th2)-high subtype of asthma is associated with 
increased epithelial expression of interleukin (IL)-4, IL-5 and IL-13 [11] and predicts a 
beneficial therapeutic response to corticosteroids [11]. Many patients with asthma have non-
eosinophilic asthma, sometimes associated with neutrophilic inflammation and/or have a 
Th2-low type of inflammation. Non-eosinophilic inflammation is associated with an impaired 
therapeutic response to inhaled corticosteroids [50,51], although the lack of efficacy may not 
be complete. Intermittent eosinophilia might be a factor accounting for corticosteroid 
sensitivity in some of this group [51]. The numbers of peripheral blood CD8(+) T cells 
expressing the leukotriene B4 (LTB4) receptor BLT1 are increased in corticosteroid resistant 
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asthma  [52]. Increased reticular basement membrane (RBM) thickness, which is a 
pathologic feature of airway remodelling, is associated with an impaired improvement in FEV1 
after a short course of systemic corticosteroids in severe asthma [53]. 
 
Corticosteroid resistant asthma  
A very small proportion of patients with severe asthma have corticosteroid resistant asthma 
defined by less than a 15% improvement in FEV1 after 2 weeks of prednisolone at a dose of 40 
mg daily. Using an alternative definition of corticosteroid resistance, based on an increase in 
morning peak expiratory flow (PEF) of < 15% following a course of oral corticosteroid, a 
retrospective study of 784 subjects with poorly controlled asthma found that 26% of subjects 
fulfilled this definition of corticosteroid resistant asthma [5].  
 
Non-adherence and poor inhaler technique 
Non-adherence with anti-asthma treatment is one of the most important reasons for poor 
symptom control and apparent corticosteroid insensitivity [54], with around a quarter of 
exacerbations estimated to be due to non-adherence with inhaled corticosteroids [55]. A high 
proportion of patients with difficult to control asthma have poor adherence with prescribed 
therapy, including both inhaled and oral corticosteroids [56]. Only a small percentage of 
inhaled corticosteroid reaches the target area in the lung, with the majority lost in the 
oropharynx or swallowed following inhalation. Good technique is paramount to ensure the 
benefits of inhaled corticosteroid treatment, although around half of all patients have poor 
inhaler technique irrespective of the device used [202].  
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Concomitant disease and misdiagnosis  
Several concomitant conditions can contribute to poor symptom control or result in 
misdiagnosis and these should be considered in the event of a poor response to treatment 
including corticosteroids. For example, psychological factors are associated with worse 
clinical outcomes in asthma and psychosocial stress has been proposed to induce 
corticosteroid insensitivity in patients with asthma due to impaired GR expression and/or 
function [57].  The therapeutic response to corticosteroids in patients considered to have the 
asthma-COPD overlap syndrome is not clearly established, but in some patients there may be 
an impaired response. 
 
Demographic variables 
 
Age and gender  
Age is positively correlated with increased in vitro peripheral blood T lymphocyte resistance 
to corticosteroids [58]. In Asthma Clinical Research Network (ACRN) trials in non-smokers 
with mild to moderate asthma, treatment failures (worsening asthma resulting in systemic 
corticosteroid use, hospitalization, emergency department visit, prolonged decrease in PEF, 
increase in albuterol use, or safety concerns including exacerbations) increased for every year 
above age 30 years in participants receiving inhaled corticosteroids [59]. The study did not 
specifically assess corticosteroid sensitivity. In the same analysis there was no difference in 
treatment failures between males and females [59].  
 
Race 
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In black people with asthma the in vitro suppressive effects of dexamethasone on PBMC T 
lymphocyte proliferation and transcriptional gene expression responses are impaired 
compared to white people with asthma [16,58]. These findings suggest that a racial 
predisposition to impaired corticosteroid responsiveness could contribute to worse asthma 
control. In contrast, patients with mild to moderate asthma recruited to ACRN clinical trials 
treated with  inhaled corticosteroids alone had no more treatment failures including 
exacerbations in African-Americans compared with white participants [60]. In a study of 
adolescents and adults with asthma, the proportion of African-Americans was not 
significantly associated with responsiveness to six weeks treatment with inhaled 
beclometasone [61].  
 
High BMI 
Mild or moderate asthmatic patients with a high body mass index (BMI) are less likely to 
achieve asthma control with inhaled fluticasone propionate treatment for 12 weeks 
compared to patients with a normal BMI [62] and have a smaller reduction in exhaled nitric 
oxide levels with inhaled corticosteroid treatment [63]. Dexamethasone induced MKP-1 
expression in vitro is blunted in PBMCs and bronchoalveolar lavage (BAL) cells in overweight 
and obese patients with asthma [64]. A cluster analysis of adults with symptomatic airflow 
obstruction identified an obese-comorbid phenotype with late-onset asthma that obtained 
improvement in quality of life, although not in PEF variability, after inhaled corticosteroids 
[65]. 
 
Pharmacokinetics of corticosteroids 
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Impaired access of inhaled corticosteroids to target cells in the airways could result in 
corticosteroid insensitivity. Airway mucosal permeability, which is increased in both normal 
smokers and in asthma or excess mucus lining the airways of asthmatic smokers could impair 
the pharmacokinetics of inhaled corticosteroids. Dysfunction of small airways is thought 
contribute to poor symptom control in severe asthma and in smokers with asthma and due to 
the reduced deposition of large particle inhaled corticosteroids to the small airways might 
contribute to corticosteroid insensitivity. The particle size of dry powder fluticasone 
propionate is increased in the presence of tobacco smoke and based on this finding it has 
been postulated that cigarette smoking could prevent the dispersion of corticosteroid into 
the small airways of the lung and hence inhaler efficacy [66]. The pharmacokinetics of oral 
prednisolone in asthma is similar to healthy controls [67]. 
 
3. Mechanisms of corticosteroids insensitivity 
 
Corticosteroids are the most effective treatment for asthma through their inhibitory actions 
on inflammatory cells and pathways involved in the pathogenesis of the disease [68]. 
Corticosteroids reduce inflammation through activation of GRs in the cytoplasm of target 
cells. The activated GR–corticosteroid complex binds to glucocorticoid-responsive elements 
(GREs) in the promoter region of corticosteroid-responsive genes within the nucleus to 
suppress (transrepression) or induce (transactivation) glucocorticoid target genes. 
Transrepression is believed to be responsible for the majority of the anti-inflammatory 
activity of corticosteroids through the reduced synthesis of proinflammatory transcription 
factors and by preventing the stimulation of inflammatory genes. The molecular mechanisms 
for the anti-inflammatory effects of corticosteroids are complex and not fully elucidated [69]. 
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However, a key mechanism is thought to involve the reversal of histone acetylation of 
activated inflammatory genes through ligand-bound GRs binding to co-activator molecules 
and subsequent recruitment of HDAC2 to the activated inflammatory gene transcription 
complex [68].  Recent studies suggest that the production of anti-inflammatory proteins may 
have a more important role in resolution of inflammation than previously considered [69].  
Corticosteroids induce histone acetylation of anti-inflammatory genes (transactivation), 
including MKP-1 and glucocorticoid-inducible leucine zipper 1 (GILZ-1) as well as potentiating 
the effects of β2 agonists, in part through increased expression of β2 adrenergic receptors on 
cell surfaces  [68]. The adverse effects of corticosteroids are thought to be due to 
transactivation of genes involved in glucose, lipid and muscle metabolism as well as by 
interacting with negative GREs to inhibit the production of osteocalcin, which is involved in 
bone synthesis  [68]. Corticosteroids also exert anti-inflammatory effects through a non-
genomic mechanism, which has a rapid onset within minutes, is of short duration and is dose-
dependent. Non-genomic mechanisms are thought to include activation of endothelial nitric 
oxide synthase (eNOS) resulting in the production of nitric oxide (NO) and the release of the 
anti-inflammatory molecule annexin-1.  
 
Several mechanisms could explain the variation between people in the response to 
corticosteroids including differences in genetic, inflammatory cell phenotypes and other 
factors discussed in section 2. Molecular mechanisms of corticosteroid insensitivity in asthma 
have been extensively reviewed in previous publications [70-72] and only a summary of the 
key mechanisms are reviewed in this article. Postulated molecular mechanisms for 
corticosteroid insensitivity in asthma include alteration in GR subtypes, defective GR binding 
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and impaired GR nuclear translocation, increased proinflammatory transcription factors 
and defective histone acetylation (Table 2).  
 
Alteration in glucocorticoid receptor subtypes 
 
GRα is a functional receptor that binds corticosteroids to induce or suppress the transcription 
of multiple genes and is the predominant GR in most inflammatory cells. Isoforms of GR are 
derived by alternative splicing and one subtype GRβ is unable to bind corticosteroids. It has 
been proposed that corticosteroid insensitivity in asthma occurs due to over expression of 
the non-functional GRβ subtype or a reduction in ligand-activated GRα subtype numbers or 
activity. GRβ expression on cells is increased by several factors associated with corticosteroid 
insensitivity in asthma including superantigens [41] and proinflammatory mediators [73] as 
well as by cigarette smoking, where the ratio of GRα to GRβ in PBMCs is reduced in cigarette 
smokers compared with never smokers [74]. Elevated GRβ expression in corticosteroid-
resistant asthma may reduce nuclear translocation of GRα and decrease HDAC2 expression in 
response to corticosteroids [75]. Overall the data is conflicting on the importance of 
alterations in the GRβ subtype in causing corticosteroid insensitivity in asthma [75,76]. A 
cluster analysis of patient with mild to moderate asthma reported that obese subjects have 
reduced expression of GCRα in PBMCs that correlates with a reduced induction of MKP-1 
expression by dexamethasone [77].  
 
Defective glucocorticoid receptor binding and nuclear translocation 
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A reduction in GR binding affinity and nuclear translocation could contribute to 
corticosteroid insensitivity through the action of pro-inflammatory mediators, such as IL-2 
and IL-4 in combination or IL-13. Cytokines are thought to induce these effects by 
phosphorylation of GR through the activation of protein kinases including p38 MAPK, JNK and 
extracellular signal-regulated kinase (ERK) [71]. Corticosteroids activate endogenous 
inhibitors of p38MAPK and JNK pathways including MKP-1 and protein phosphatase 2A 
(PP2A) [71,78]. The expression of the anti-inflammatory protein MKP-1 is reduced in alveolar 
macrophages from patient with severe asthma associated with corticosteroid insensitivity 
[79] and in PBMCs from overweight and obese patients with asthma [64,77]. In a mouse 
model, the translocation of GR to the nucleus is inhibited by IFN-γ producing cells and LPS 
cooperating to produce IL-27 from macrophages through activation of toll-like receptor 
(TLR)4 and MyD88 dependent pathways [80]. Furthermore, IFN-γ  and LPS induce miR-9 
expression in lung tissue and primary macrophages, which reduces PP2A activity [81]. 
Corticosteroid induced GRα nuclear translocation is suppressed by rhinovirus infection in 
airway epithelium through JNK activation [46]. Recently asthmatic children clinically classified 
as poor corticosteroid responders were reported to have reduced GR bioavailability due to 
decreased GR protein expression and more rapid corticosteroid-induced down regulation 
compared to asthmatic children classified as good corticosteroid responders [82]. 
 
Increase in proinflammatory transcription factors 
 
Activation of pro-inflammatory transcription factors such as NF-κB, activator protein-1 (AP-1) 
and signal transduction-activated transcription factors (STAT) enable the translation of 
inflammatory genes and recruiting of inflammatory cells and could cause corticosteroid 
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insensitivity. Increased nuclear factor-κB (NF-κB) expression in PBMCs has been associated 
with corticosteroid insensitivity in severe asthma [83] and as tobacco smoke activates NF-κB, 
this transcription factor which might contribute to reduced response to corticosteroids in 
smokers with asthma. Dysregulation of AP-1 is associated with corticosteroid resistant 
asthma [84]. Rhinovirus infection induce corticosteroid resistance in airway epithelium by the 
activation of NF-κB [46]. 
 
Defective histone acetylation 
 
Corticosteroids require HDAC activity for maximal suppression of inflammatory cytokine 
induction [85]. Low levels of HDAC2 expression are found in PBMCs [86] and alveolar 
macrophages [87] in patients with severe asthma, which is thought to be due to excessive 
oxidative stress [71]. Smokers have decreased HDAC2 activity in alveolar macrophages, 
possibly as a result of oxidative and nitrative stress and this may lead to increased 
inflammatory gene expression and reduced sensitivity to corticosteroids [88,89]. Oxidative 
stress activates phosphinositide 3-kinase (PI3K) resulting in AKt phosphorylation and HDAC2 
inactivation [71]. 
 
Other immune mechanisms 
 
Suppression of the anti-inflammatory cytokine IL-10 production by T lymphocytes  in asthma 
could contribute to corticosteroid insensitivity [90]. The pro-inflammatory mediator TNFα 
induces corticosteroid insensitivity in a mouse model of neutrophilic airway inflammation 
[91]. 
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4. Current management of corticosteroid insensitivity 
 
The aims of management are to achieve good asthma control and to minimize treatment burden, 
especially from oral corticosteroid use, although achieving these aims in severe asthma is often 
difficult. A step-wise approach to treatment should be integrated into a management plan that 
includes assessment of adherence and inhaler technique, non-pharmacological treatments where 
appropriate, as well as supported self-management [201, 202]. It is important to distinguish 
patients with severe asthma from those with ‘difficult to control’ asthma due to reasons other 
than disease severity by undertaking a systematic evaluation [92]. For adults and adolescents with 
asthma patients who have poor symptom control or who at risk of exacerbations and in whom the 
diagnosis of asthma has been confirmed, guidelines recommend daily inhaled corticosteroid as the 
preferred controller treatment, with the addition of add-on therapies if symptoms remains poorly 
controlled [201, 202]. However, this approach may result in up to one third of patients failing to 
obtain maximal improvement in asthma control and quality of life due to corticosteroid 
insensitivity. Several management strategies that address specific factors associated with an 
impaired therapeutic response to corticosteroids may result in improvements in asthma control 
(Table 3). 
 
Non-adherence 
 
The ability to detect poor adherence based on history alone is poor. Adherence can be assessed 
by reviewing prescription refill frequency and by measuring circulating blood prednisolone 
concentration in patients taking oral corticosteroids. A trial of a parenteral depo corticosteroid 
can help establish whether persistent symptoms are due to poor adherence with inhaled and/or 
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oral corticosteroids. Strategies to improve adherence include adequate explanation of 
the indications for treatment, discussion of real and perceived concerns of adverse effects of 
treatment, simplifying drug treatment regimens, reminders and reinforcement [54]. Improving 
medication adherence could have a substantial beneficial impact on asthma related clinical 
outcomes [93]. 
 
Non-pharmacological interventions  
 
There is limited information on the effectiveness of non-pharmacological interventions for the 
management of factors associated with corticosteroid insensitivity in asthma (Table 1). A small 
number of studies have examined the role of smoking cessation on asthma outcomes and 
reported improvements in symptoms and lung function in those people who quit smoking 
successfully [30]. Smoking cessation in asthma is associated with improvement in corticosteroid 
sensitivity [15,94]. Weigh reduction in asthmatic patients with a high BMI may result in 
improvements in asthma symptoms [95], although whether corticosteroid sensitivity also 
improves is not reported.  
 
Anti-inflammatory and corticosteroid-enhancing actions of vitamin D are reported in monocytes of 
patients with corticosteroid-resistant asthma and those with steroid-sensitive asthma, although 
the responses to corticosteroids remains lower than in patients with corticosteroid sensitive 
asthma [96,97].  Peripheral blood CD4+ T cells isolated from subjects with corticosteroid-resistant 
asthma regain their sensitivity to corticosteroids following a short course of oral vitamin D through 
the induction of IL-10 [98]. Based on these findings, several clinical trial have examined the effect 
of dietary supplement of vitamin D in asthma. A small clinical trial of vitamin D3 supplementation 
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in patients with corticosteroid resistant asthma demonstrated a modest improvement in 
lung function after a short course of oral prednisolone and an increase in dexamethasone-induced 
IL-10 production in vitro as well as suppression of dexamethasone-induced IL-17A production 
[99,100]. Two large randomized clinical trials of vitamin D3 supplementation in patients with 
asthma and vitamin D insufficiency [VIDA and ViDiAs trials), although not selected for 
corticosteroid insensitivity, reported no improvements in clinical outcome [101,102]. Interestingly, 
vitamin D supplementation reduced eosinophilic inflammation in patients with non-atopic asthma, 
suggesting that certain phenotypes might obtain benefit from vitamin D3 supplementation [103]. 
 
Current pharmacological treatments 
  
A step-up in the dose of corticosteroid as well as the addition of other therapies may benefit 
individuals with asthma that is associated with corticosteroid insensitivity. 
 
Inhaled corticosteroids 
The relatively flat dose response to inhaled corticosteroids in asthma results in the majority 
of the therapeutic benefits being achieved at low to medium doses [1]. In the Gaining 
Optimal Asthma Control (GOAL) trial, high dose inhaled corticosteroids treatment with 
inhaled fluticasone propionate 1000 mcg daily resulted in clinical improvements in asthma 
control, although in patients with more severe disease only 50% achieved well controlled 
asthma and 20% achieve totally control [2] [201].  In a short-term study in smokers with mild 
asthma who demonstrated corticosteroid insensitivity to low dose inhaled corticosteroids 
there was an improvement in lung function with high dose inhaled corticosteroid treatment 
[31]. Targeting the small airways with extrafine-particle inhaled corticosteroids may 
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potentially impact favorably on the safety and efficacy of inhaled corticosteroids through 
improved total lung deposition and resulting in improved asthma control at lower daily doses 
than the large-particle inhaled corticosteroid. Observational studies suggest that extrafine 
particle HFA-BDP Qvar may achieve better control at lower prescribed doses than large 
particle inhaled corticosteroids [104], but to date randomized controlled trials have not 
clearly demonstrated that equipotent doses of small-particle inhaled corticosteroids are more 
effective than large-particle inhaled corticosteroids. 
 
LABAs in combination with inhaled corticosteroids 
The combination of a LABA and an inhaled corticosteroid may act synergistically to increase 
corticosteroid sensitivity of inflammatory cell in severe asthma and in smokers with asthma.  
Long acting β2-agonists have been shown in vitro to increase the translocation of GRs to the 
nucleus. The LABA formoterol increases corticosteroid sensitivity in vitro through inhibition of 
GR phosphorylation via  PP2A activation in a β2-receptor independent manner [105]  and by 
inhibition of PI3K signaling [106].  In addition, formoterol enhances  the expression of the 
anti-inflammatory transcription factor MKP-1 induced by corticosteroids [107].   
 
Low dose theophylline 
Low dose theophylline restores corticosteroid sensitivity in-vitro possibly by increasing HDAC2 
activity, which is suppressed in severe asthma and in smokers and a similar clinical effect 
might occur in asthma[108]. An exploratory study examined the impact of low dose 
theophylline added to inhaled corticosteroid compared to inhaled corticosteroid alone in a 
group of smokers with asthma [109] (Figure 3).   The addition of theophylline to inhaled 
corticosteroid, at a dose titrated to provide a ‘sub-therapeutic’ concentration, resulted in 
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increased efficacy as measured by lung function and suggested the restoration of 
corticosteroid sensitivity in those treated with the combination. Theophylline inhibits 
oxidative stress dependent PI3K-δ activation and restores corticosteroid sensitivity in PBMCs 
from patients with COPD [108]. Clinical trials have not investigated the therapeutic effects of 
adding low dose theophylline in patients with severe asthma. A fixed combination of ultra-
low dose of theophylline with fluticasone, SKP-2075 is under development for the treatment 
COPD. This combination would potentially be of benefit in the treatment of corticosteroid 
insensitivity in severe asthma and in smokers with asthma. 
 
Leukotriene-receptor antagonist 
A randomized controlled trial that compared oral montelukast (10 mg daily), inhaled 
fluticasone propionate (500 µg daily), and placebo over a 6-month treatment period in mild 
smokers with asthma [110] reported that less than 50 percentage of days with asthma 
control during each treatment, although both active treatments were better than placebo. 
Patients with a smoking history of <11 pack years tended to show greater benefit with 
fluticasone, whereas those with a smoking history of >11 pack years tended to show greater 
benefit with montelukast. 
 
Oral corticosteroid sparing therapies 
Some biological agents and immunosuppressive agents have oral corticosteroid sparing effects in 
patients with severe asthma who have uncontrolled symptoms despite treatment that includes 
high dose inhaled corticosteroids and LABAs, although it is unclear whether the reduction in daily 
oral corticosteroids is due to a reversal of corticosteroid insensitivity or due to the intervention 
targeting corticosteroid insensitive inflammatory pathways. Omalizumab is a humanised 
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monoclonal antibody that binds circulating IgE antibody produces improvements in 
quality of life and reductions in exacerbations [111] as well as possibly having oral 
corticosteroid-sparing effects. An anti-IL-5 monoclonal antibody mepolizumab, which blocks the 
binding of IL-5 to IL-5 receptor-α on the surface of eosinophils, decreases severe exacerbations 
[112] and reduces the use of oral corticosteroids [113]. Mepolizumab was recently licensed in the 
US for use in patients with severe eosinophilic asthma.  
 
5. Potential future therapies for corticosteroid insensitivity 
 
Many patients with asthma that is associated with corticosteroid insensitivity continue to have 
poorly controlled disease despite treatment with currently available therapies. There is an unmet 
need for new treatments that will impact favorably on clinical outcomes in these patients 
through the restoration of corticosteroid sensitivity (Table 4). Novel small molecule drugs and 
biologics agents have been developed as possible new treatments for asthma, including for 
patients with corticosteroid insensitivity. Several drugs licensed for the treatment of medical 
conditions other than asthma have been investigated for their efficacy in asthma. Candidate 
drugs have been chosen usually because of pre-clinical evidence of effects on reduction 
inflammation and restoring corticosteroid sensitivity that might be relevant to the treatment of 
asthma. Potential therapies for patients with severe refractory asthma associated with 
corticosteroid insensitivity are summarized below. 
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Small molecule drugs 
 
Macrolides 
The mechanism(s) of action of macrolides in the treatment of airway diseases is not established, 
but could be due to their antibacterial and/or anti-inflammatory actions, which include inhibition 
of NF-κB and other transcription factors as well as  reduction in IL-8 production, neutrophil 
migration and/or function [114,115]. Additionally, macrolides may restore corticosteroid 
sensitivity by inhibiting PI3K activation [116] and TNFα/IL-17 immune responses [117]. Two 
recent exploratory clinical trials have investigated the effects of macrolides in non-eosinophilic 
asthma associated with corticosteroid insensitivity. In the first trial, seventy-seven smokers with 
mild to moderate asthma were randomized to a double-blind parallel-group trial comparing 
azithromycin [250 mg per day] with placebo [118].  At 12 weeks, treatment with azithromycin did 
not improve symptom control or lung function. In the second randomized controlled trial non-
smokers with exacerbation-prone severe asthma received low-dose azithromycin (n=55) or 
placebo (n=54) as add-on treatment to combination therapy of inhaled corticosteroids and LABA 
for 6 months [119]. Azithromycin did not reduce the rate of severe exacerbations and lower 
respiratory tract infections requiring treatment with antibiotics in the total study population. In a 
predefined subgroup there was a reduction in the rate of primary endpoints in azithromycin-
treated patients with non-eosinophilic severe asthma (blood eosinophilia ≤200/µl) [119]. Novel 
analogues of macrolides have been developed that have greater anti-inflammatory effects than 
current macrolides, such as solithromycin (CEM-101) [115,116] or that lack anti-bacterial 
properties but retain anti-inflammatory activity, such as the non-antibiotic azithromycin 
derivative CSY0073 [120].  
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Protein kinase inhibitors 
Inhibition of protein kinase, such as p38MAPK, narrow spectrum kinase and tyrosine kinase, 
that are involved in cellular signaling of pro-inflammatory cytokines, may have a role in the 
treatment of severe asthma associated with corticosteroid insensitivity [121-123]. Several 
p38MAPK inhibitors restore corticosteroid sensitivity in PBMCs from patients with severe 
asthma [121,124] and COPD [125]. Clinical trials of p38MAPK inhibitors, such as oral 
losmapimod (GW856553) and inhaled AZD7624 are underway in COPD, although none are 
registered in asthma. A specific ckit tyrosine kinase inhibitor imatinib inhibits 
hyperresponsiveness, inflammation and remodeling in murine asthma models [126] and is 
undergoing clinical trial evaluation in severe refractory asthma (ClinicalTrials.gov Identifier: 
NCT01097694). A tyrosine kinase inhibitor masitinib that targets c-kit and the platelet-derived 
growth factor (PDGF) receptor improved asthma control in patients with severe 
corticosteroid-dependent asthma [127] and a further clinical trial is underway in patients with 
severe persistent asthma treated with oral corticosteroids (ClinicalTrials.gov Identifier:  
NCT01449162).  
 
PI3kinase inhibitors 
Pre-clinical studies suggest that PI3K-δ inhibitors could potentially reverse corticosteroid 
insensitivity by increasing HDAC2 activity [128,129]. Selective PI3K inhibitors are being 
developed as novel treatments of corticosteroid insensitive airway diseases. An inhaled PI3Kδ 
inhibitor GSK2269557 is undergoing clinical trials in adults with persistent uncontrolled 
asthma (ClinicalTrials.gov Identifier: NCT02567708). PI3K δ and γ isoforms are implicated in 
inflammatory cell recruitment and activation [129]. An inhaled dual PI3Kδ/γ inhibitor, TG100-
115, reduces airway inflammation induced by allergen and cigarette smoke in murine models 
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and restores corticosteroid sensitivity in the smoke model [130]. A PI3Kδ/γ inhibitor 
RV1729 has undergone early stage clinical evaluation in COPD, although no results are 
published (ClinicalTrials.gov Identifier: NCT02140346). The tricyclic antidepressant 
nortriptyline reverses corticosteroid insensitivity induced by oxidative stress in vitro by 
inhibition of PI3K-δ and it has been proposed as a potential treatment for corticosteroid-
insensitivity in severe asthma, smokers with asthma and COPD [131]. 
 
NF-κB inhibitors 
Targeting activation of the pro-inflammatory transcription factor NF-κB with inhibitors of IκB 
kinases (IKKs) may restore corticosteroid sensitivity in severe asthma and smokers with 
asthma [132], although adverse effects may limit the use of these compounds. 
 
PDE4 inhibitors and dual PDE3 and PDE4 inhibitors 
Phosphodiesterase (PDE)4 inhibitors have immunomodulatory properties relevant to the 
treatment of asthma including the restoration of corticosteroid sensitivity  [133]. The oral PDE4 
inhibitor roflumilast reverses corticosteroid resistance in peripheral blood neutrophils from 
patients with COPD [134]. High doses of PDE4 inhibitors may be necessary to treat severe 
asthma, although gastro-intestinal side effects limit their use. Inhaled formulations may improve 
the therapeutic ratio of PDE4 inhibitors [135-137]. The inhaled PDE4 inhibitor GSK256066 inhibits 
allergen-induced late asthmatic responses [136] and in patients with moderate COPD GSK256066 
was well tolerated although there was no inhibitory effect on inflammatory biomarkers in 
sputum and blood [138]. The combination of selective PDE3 and PDE4 inhibitors prevent 
corticosteroid insensitivity induced by oxidative stress in human alveolar macrophages [139]. A 
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inhaled dual PDE3 and PDE4 inhibitor, RPL554 has bronchodilator effects and is well 
tolerated in patients with asthma and COPD [140].  
 
PPARγ agonists 
Peroxisome proliferator-activated receptor-γ (PPARγ) agonists are members of the nuclear 
receptor family that exert in pre-clinical studies anti-inflammatory effects potentially relevant to 
the treatment of airway diseases and to restoring corticosteroid sensitivity [141,142]. A proof of 
concept study using the oral PPARγ agonist rosiglitazone demonstrated bronchodilator effects in 
mild to moderate smokers with asthma who had non-eosinophilic inflammation [143]. A 
borderline reduction in sputum IL-8 was observed with rosiglitazone compared with inhaled 
beclometasone dipropionate. The adverse-effect profile of oral rosiglitazone has precluded its 
development as a treatment for asthma. Inhaled PPARγ agonist analogues, such as ADC3277 
should facilitate further examination of this potential novel approach to the treatment of 
corticosteroid insensitive airway disease.  
 
Statins  
Statins reduce cholesterol biosynthesis by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase and in addition have pleiotropic immunomodulatory effects  that may 
be of value for the treatment of chronic inflammatory diseases [144,145]. Preclinical in vitro 
and in vivo studies, including experimental models of allergic [146] and tobacco-smoke-
induced lung inflammation [147] found that statins reduce components of airway 
inflammation potentially relevant to the pathogenesis of asthma and smoke-induced airway 
diseases. Statins may also restore corticosteroid sensitivity in asthma [148,149]. In smokers 
with asthma the effects of atorvastatin alone and in combination with inhaled corticosteroid 
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was investigated on the ability to suppress the concentration of a range of cytokines, 
chemokines and growth factors in sputum [150,151].  Despite the absence of a suppressive 
effect of inhaled beclometasone on sputum mediators, atorvastatin either alone or in 
combination with inhaled beclometasone reduced sputum concentrations of approximately 
one-third of the selected cytokines, chemokines and growth factors. Atorvastatin significantly 
reduced sputum concentrations of CCL7, IL-12p70, sCD40L, FGF-2, CCL4, TGF-α and MMP-8 
compared with placebo and, when combined with inhaled beclometasone, reduced sputum 
concentrations of MMP-8, IL-1β, IL-10, MMP-9, sCD40L, FGF-2, IL-7, G-CSF and CCL7 
compared to inhaled beclometasone alone (Figure 4). Improvements in ACQ and/or AQLQ 
scores with atorvastatin and inhaled corticosteroid were associated with decreases in G-CSF, 
IL-7, CCL2 and CXCL8. Interestingly, simvastatin suppresses airway IL-17 and upregulated IL-10 
in patients with stable COPD [152].  Taken together, these findings suggest that treatment 
with atorvastatin either alone or in combination with an inhaled corticosteroid may be of 
benefit in certain corticosteroid insensitive airway diseases. There is a need for long-term 
clinical studies examining effect of statins on exacerbations, neutrophil function and airway 
remodeling in severe asthma associated with corticosteroid insensitivity. 
 
Drugs targeting neutrophilic inflammation 
As increased airway neutrophils have implicated as a potential cause corticosteroid 
insensitivity in asthma, small molecule drugs have been developed to treat asthma that target 
these cells including CXCR2 antagonists in asthma [153,154] and COPD [155] and a 5-
lipoxygenase-activating protein (FLAP) inhibitor GSK2190915 in asthma [156], although their 
ability to restore corticosteroid sensitivity has not been studied. In addition, evidence for the 
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clinical effectiveness of CXCR2 antagonists and FLAP inhibitors in chronic asthma is so far 
lacking. 
 
Biological agents 
 
Pre-clinical studies suggest a possible role for Th17 cells and IL-17 in neutrophilic asthma and 
corticosteroid insensitivity [157]. Increased levels of IL-17 are found in BAL, sputum and 
bronchial biopsy samples obtained from patients with severe asthma and correlates with 
sputum neutrophils. Brodalumab is a human monoclonal antibody that binds with high 
affinity to human IL-17RA, blocking the biologic activity of IL-17A, -17F, -17A/F heterodimer, 
and IL-25. A randomized clinical trial of  brodalumab administered for 12 weeks to 302 adults 
with inadequately controlled moderate to severe asthma taking regular inhaled 
corticosteroids found no treatment difference in ACQ score or in secondary endpoints 
including FEV1 and symptom-free days [158]. In a pre-specified subgroup with high 
bronchodilator reversibility that accounted for 37% of the full study population there was a 
borderline improvement an ACQ score. The clinical trial did not select patients with 
neutrophilic inflammation. A follow-up clinical trial of brodalumab in inadequately controlled 
asthma subjects with high bronchodilator reversibility was recently terminated 
(ClinicalTrials.gov Identifier: NCT01902290). A clinical trial of the IL-17A monoclonal antibody 
blocker secukinumab in patients with uncontrolled asthma has also been recently terminated 
(ClinicalTrials.gov Identifier: NCT01478360). Neutralizing TNFα restores corticosteroid 
sensitivity in a mouse model of neutrophilic airway inflammation [91]. Despite some promise 
shown in early small clinical studies with the soluble TNF-α receptor blocker etanercept in 
severe asthma, larger studies with golimumab [159] and etanercept [160] did not confirmed a 
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consistent effect. Overall, when combined with concerns over increased risk of severe 
infections and malignancies with treatment [159] it is unlikely that TNF-α receptor blockers 
will be developed further for the treatment of asthma. Monoclonal antibodies that block 
IL-1β, for example, canakinumab might be of benefit in corticosteroid insensitive asthma, 
although no clinical studies are currently registered. 
 
6. Expert commentary 
 
Corticosteroids are the most effective treatment for asthma, but the therapeutic response 
differs markedly between individuals. Corticosteroid insensitivity may be clinically important 
in up to a third of patients with asthma particularly in people with severe disease. Multiple 
factors including genetic, environmental such as cigarette smoking and asthma-related such 
as non-adherence and non-eosinophilic inflammation as well as demographic variables are 
likely to account for the heterogeneous response to corticosteroids between people. 
Advances in the understanding the molecular mechanisms of corticosteroids have led to 
important insights into the pathways involved in corticosteroid insensitivity in asthma 
including alterations in GR subtypes, defective GR binding and nuclear translocation, 
increased proinflammatory transcription factors and defective histone acetylation as well as 
other immunological mechanisms. Nevertheless, the underlying mechanisms of corticosteroid 
insensitivity in asthma are only partly understood. In the future system biology approaches 
may produce new insights to understanding corticosteroid insensitivity [72]. 
 
Non-adherence with inhaled and oral corticosteroid treatment is one of the most important 
reasons for poor symptom control and apparent corticosteroid insensitivity. There is limited 
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information on the effectiveness of non-pharmacological interventions for the 
management of asthma on specific factors associated with corticosteroid insensitivity in asthma. 
Advice on smoking cessation is essential in smokers with asthma and may improve corticosteroid 
responsiveness.  
 
A step-up in the dose of corticosteroid as well as the addition of other therapies for asthma may 
benefit some individuals with asthma that is associated with corticosteroid insensitivity. High 
dose inhaled corticosteroids treatment improves clinical outcomes in some patients with severe 
asthma and in smokers with asthma, but many patients remain symptomatic. Long acting β2-
agonists have been shown in vitro to increase the translocation of GR to the nucleus and to be of 
clinical benefit. In an exploratory clinical trial in smokers with asthma low dose theophylline 
added too inhaled corticosteroid resulted in improvement in lung function and suggested the 
restoration of corticosteroid sensitivity in those treated with the combination. It is not known 
whether a similar beneficial effect is achieved with low dose theophylline in severe asthma. 
Some biological agents such as omalizumab and mepolizumab and immunosuppressive agents 
such as methotrexate have oral corticosteroid sparing effects in patients with severe asthma 
although it is not known whether the reduction in daily oral corticosteroids is due to a reversal of 
corticosteroid insensitivity. 
 
Many patients with asthma continue to have poorly controlled disease that is associated with 
corticosteroid insensitivity despite receiving treatment with currently available therapies. Small 
molecule drugs such as macrolides, various protein kinase inhibitors, PI3 kinase inhibitors, NF-κB 
inhibitors, PDE4 and PDE3/PDE4 inhibitors, PPARγ agonists as well as statins might be shown to be 
of benefit in the treatment of corticosteroid insensitive airway diseases. The results of clinical 
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trials of biological agents such as monoclonal inhibitors of IL-17 has been disappointing to 
date. Future clinical trials will determine which of these therapies will ultimately be licensed for 
the treatment of asthma and in particular will be of value in the treatment of corticosteroid 
insensitivity.  
 
7. Five-year review 
 
The management of patients with asthma is often hampered because it is currently difficult 
to identify whether poorly controlled symptoms are due to corticosteroid insensitivity or to 
other reasons such as non-adherence or the involvement of corticosteroid insensitive 
inflammatory pathways. The development of biomarkers that can identify corticosteroid 
insensitivity in the clinic would greatly aid in the management of patients with uncontrolled 
asthma and lead to a personized approach to treatment. Over the last 15 years several 
international collaborative programmes of research have investigated pathogenic mechanism 
of severe asthma and corticosteroid insensitivity [161,162]. A recent international collaborate 
project in severe asthma, the Unbiased Biomarkers for the Prediction of Respiratory Disease 
Outcome (U-BOPRED) study, is designed to identify new phenotypes/endotypes and 
treatment targets using omics technologies and applying a system biology approach. It is due 
to report its main findings shortly [163]. The UK Refractory Asthma Stratification Programme 
(RASP-UK) is investigating novel biomarker stratification strategies in severe asthma, 
assessing adherence to corticosteroids and examining biomarkers to optimise corticosteroid 
treatment [164]. Hopefully the findings from these research networks will identify new 
approaches to the treatment of patients with severe corticosteroid insensitive asthma. 
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Key issues 
 
 
• Corticosteroids are the most effective treatment for asthma, but the therapeutic 
response varies markedly between individuals, with up to one third of patients showing 
evidence of insensitivity to corticosteroids.  
• Multiple factors including genetic, environmental such as cigarette smoking and asthma-
related factors such as non-adherence and non-eosinophilic inflammation as well as 
demographic and pharmacokinetic variables are likely to contribute to the heterogeneous 
response to corticosteroids between people.  
• Molecular mechanisms proposed to explain corticosteroid insensitivity include alterations 
in GR α and β subtypes, impaired GR binding and nuclear translocation, increased 
proinflammatory transcription factors and defective histone acetylation.  
• Non-adherence with inhaled and oral corticosteroid treatment is one of the most important 
reasons for poor symptom control and apparent corticosteroid insensitivity.  
• There is limited information on the effectiveness of non-pharmacological interventions for 
the management of asthma on specific factors associated with corticosteroid insensitivity in 
asthma. Advice on smoking cessation is essential in smokers with asthma and may improve 
corticosteroid responsiveness.  
• A step-up in the dose of corticosteroid as well as the addition of other therapies for 
asthma may benefit some individuals with asthma that is associated with corticosteroid 
insensitivity. High dose inhaled corticosteroids treatment improves clinical outcomes in 
some patients with severe asthma and in smokers with asthma, but many patients remain 
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symptomatic. Long acting β2-agonists have been shown in vitro to increase the 
translocation of GR to the nucleus. In an exploratory clinical trial in smokers with asthma 
low dose theophylline added too inhaled corticosteroid resulted in improvement in lung 
function and suggested the restoration of corticosteroid sensitivity in those treated with 
the combination. 
• Future interventions that may restore corticosteroid sensitivity in asthma include small 
molecule drugs such as macrolides, several protein kinase inhibitors, PI3 kinase inhibitors, 
NF-κB inhibitors, PDE4 and PDE3/PDE4 inhibitors, PPARγ agonists as well as statins and 
biological agents. 
• In the future, biomarkers may be used in the clinic to predict corticosteroid insensitivity in 
patients with poorly controlled asthma. 
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Table 1: Factors that potentially influence the therapeutic response to corticosteroids in 
patients with asthma  
 
Genetic factors 
T-box expressed in T cells21 (TBX21) polymorphisms  
Corticotrophin-releasing hormone receptor 1 gene (CRHR1) polymorphisms  
Low-affinity IgE receptor gene (FCER2) polymorphisms  
Glucocorticoid-induced transcript 1 gene (GLCCI1) polymorphisms  
T gene polymorphisms  
chr6 rs6924808 and chr11 rs1353649 polymorphisms  
 
Environmental factors 
Active and secondhand exposure to cigarette smoke 
Allergen exposure 
Infections: superantigens, airway microbiome, viruses 
Endotoxin 
Vitamin D deficiency 
 
Asthma associated factors 
Airway inflammatory cell phenotypes and airway remodeling 
Corticosteroid resistant asthma 
Non-adherence and poor inhaler technique 
Concomitant disease and misdiagnosis 
 
Demographic variables 
Age  
Gender  
Race 
Body mass index 
 
Pharmacokinetics of corticosteroids 
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Table 2 Examples of potential mechanisms of corticosteroids insensitivity in asthma 
 
Alteration in glucocorticoid receptor (GR) subtypes 
Reduction in ligand-activated GRα subtype numbers or activity 
Over expression of the non-functional GRβ subtype 
 
Defective glucocorticoid receptor binding and nuclear translocation 
Reduction in GR binding affinity and nuclear translocation  
 
Increase in proinflammatory transcription factors 
Activation of pro-inflammatory transcription factors such as nuclear factor-κB (NF-κB), 
activator protein-1 (AP-1) and signal transduction-activated transcription factors (STAT) 
 
Defective histone acetylation 
Reduction in histone deacetylase (HDAC) 2 activity 
 
Other immune mechanisms 
Suppression of the anti-inflammatory cytokine interleukin (IL)-10 production  
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Table 3 Current management of corticosteroid insensitivity in asthma 
 
Non-adherence 
Employ strategies to improve adherence 
 
Non-pharmacological interventions  
Smoking cessation  
Weight reduction ‡  
Dietary supplementation with vitamin D3 ‡ 
 
Current pharmacological treatments 
 
Inhaled corticosteroids 
Step-up in dose of inhaled corticosteroid 
Extrafine-particle inhaled corticosteroid ‡ 
Combination of a long acting β2-agonists (LABA) and an inhaled corticosteroid 
Addition of low dose theophylline to an inhaled corticosteroid 
‡‡
 
Leukotriene-receptor antagonist 
‡‡
 
Oral corticosteroid sparing therapies 
‡‡‡
 
Biological agents e.g. omalizumab, mepolizumab 
Immunosuppressive agents e.g. methotrexate 
 
Notes 
‡
  Not proven to reverse corticosteroid insensitivity in asthma 
‡‡  
Possibly in smokers with asthma
  
‡‡‡  
Unclear whether the reduction in daily oral corticosteroids is due to a reversal of corticosteroid insensitivity 
or due to the intervention targeting corticosteroid insensitive inflammatory pathways 
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Table 4 Examples of potential future therapies for corticosteroid insensitivity 
 
Small molecule drugs 
 
Macrolides 
Protein kinase inhibitors 
p38 Mitogen-activated protein kinase (MAPK) inhibitors 
Narrow spectrum kinase inhibitors 
Tyrosine kinase inhibitors 
Phosphinositide 3 (PI3)-kinase inhibitors 
PI3K-δ inhibitors  
Dual PI3Kδ/γ inhibitors 
Nuclear factor κB (NF-κB) inhibitors 
IκB kinases (IKKs) inhibitors 
Phosphodiesterase (PDE) inhibitors  
PDE4 inhibitors  
Dual PDE3 and PDE4 inhibitors  
Peroxisome proliferator-activated receptor-γ (PPARγ) agonists  
Statins  
Drugs targeting neutrophilic inflammation 
C-X-C chemokine receptor (CXCR)2 antagonists  
5-lipoxygenase-activating protein (FLAP) inhibitors 
 
Biological agents 
 
Interleukin (IL)-17A receptor blockers 
IL-17A blockers 
Tumour necrosis factor (TNF)-α receptor blockers 
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FIGURE LEGENDS 
 
Figure 1 Variation in therapeutic response to oral corticosteroids in adults with asthma 
 
Distribution of treatment response for change in morning peak expiratory flow (PEF) after a 
short course of oral corticosteroid in 784 adults with asthma. Reprinted with permission from 
[5]. 
 
Figure 2 Association of serum endotoxin and therapeutic response to oral corticosteroids in 
adults with asthma 
 
Association of percentage change in FEV1 after oral corticosteroids with sputum endotoxin 
concentrations in asthmatic patients. The linear regression line (solid line) with the true 95% 
CI (dashed lines) of nonsmokers (open circles) and smokers (red squares) is shown. In the 
combined asthma group the percentage change in FEV1 after oral dexamethasone decreased 
with increasing sputum endotoxin concentration (Spearman rho: r 520.329 [95% CI, 20.570 to 
20.036], p=0.029). Reprinted with permission from [48]. 
 
Figure 3 Addition of low-dose theophylline to inhaled betametasone in smokers with 
asthma 
 
An exploratory study examined the impact of low dose theophylline added to inhaled 
corticosteroid (betametasone, BDP) compared to inhaled corticosteroid (BDP) alone in a 
group of smokers with asthma. Change in peak expiratory flow (PEF) from randomization to 
28 days of treatment. Adapted from [109]. 
 
Figure 4 Sputum mediator concentrations after atorvastatin and atorvastatin plus inhaled 
beclometasone or beclometasone alone in smokers with asthma 
 
Sputum mediator concentrations after atorvastatin treatment or placebo and atorvastatin 
plus inhaled beclometasone or beclometasone alone in smokers with asthma.  Examples of 
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sputum cytokine (IL-1β, G-CSF), chemokine (CCL7) or growth factor (FGF) concentrations 
after atorvastatin treatment or placebo and atorvastatin plus inhaled beclometasone or 
beclometasone alone.  
Abbreviations: CCL: chemokine (C-C motif) ligand; FGF: Fibroblast growth factor; G-CSF: 
Granulocyte colony stimulating factor; IL: Interleukin; NS: not significant. Horizontal bar 
indicates Median (IQR). Adapted from [151]. 
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